This focused series on “HCC in the Era of DAAs” is edited by Dr. Gamal Shiha from Hepatology and Gastroenterology Unit, Internal Medicine Department, Faculty of Medicine, Mansoura University, Egypt.
This series outlines the pathogenesis of HCV-related Hepatocellular carcinoma (HCC), which may facilitate the understanding of HCV-related oncogenesis, the incidence rates of HCC in relation to dynamic changes of liver fibrosis following direct acting antivirals and the available data on the impact of new direct-acting antiviral treatment on HCC recurrence.
Impact of viral clearance following direct acting antivirals on hepatocellular carcinoma
Pathogenesis of hepatitis C virus-related hepatocellular carcinoma: evidence from recent studies
Incidence rates of hepatocellular carcinoma in relation to dynamic changes of liver fibrosis following viral clearance
Direct-acting antivirals and hepatocellular carcinoma recurrence
Disclosure:
The series “HCC in the Era of DAAs” was commissioned by the editorial office, Journal of Public Health and Emergency without any sponsorship or funding. Gamal Shiha is serving as the unpaid Guest Editor for the series.